Where it trades today
trading 92% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DXCM trades at 35.3x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- DXCM carries a beta of 1.42, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- DXCM is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in DXCM.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DXCM come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DXCM. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What DexCom Inc. does
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and…
What analysts expect
DXCM carries a strong buy consensus from 25 analysts, with an average price target of $94.48 versus $89.35 today (+5.7%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DXCM generated $4.97B in trailing revenue (13.1% year over year), with a 20.1% net margin, and $1.02B of free cash flow, supported by $548.60M of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.66B | $2.80B | $911.80M | $836.30M | $2.14 | $1.08B |
| 2024 | $4.03B | $2.44B | $600.00M | $576.20M | $1.46 | $630.70M |
| 2023 | $3.62B | $2.29B | $597.70M | $541.50M | $1.40 | $511.90M |
| 2022 | $2.91B | $1.88B | $391.20M | $341.20M | $0.88 | $304.70M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DXCM beside the healthcare names it is usually measured against.
What the chart is saying
DexCom Inc. trades at $89.35, 3.5% below its 52-week high. With a beta of 1.42, it shows more sensitivity to what the wider market does.
Questions people ask about it
Is DXCM a good buy right now?
DexCom Inc. trades at 35.3x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 24.4% volatility.
Does DXCM pay dividends?
DexCom Inc. does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is DXCM?
With 30-day annualized volatility of 24.4% and beta of 1.42, DXCM is classified as Medium risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for DXCM?
The average analyst price target for DexCom Inc. (DXCM) is $94.48 based on 25 analyst estimates, about 5.7% above the current price of $89.35. The published range runs from $79.00 to $115.00.
How much revenue does DXCM generate?
DexCom Inc. reported $4.97B in trailing twelve-month revenue. Revenue growth is running at 13.1% year over year. Net margin sits at 20.1%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.